Global Viral Vector Manufacturing Market Key Players, Size, Demands, End users, Application and Forecasts to 2028

The global viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the availability of funding for the development of gene therapy. Gene therapy is a rapidly growing field, and funding is needed for research and development, clinical trials, and manufacturing. For instance, in December 2022, SonoThera, a biotechnology company announced completion of its USD 60.75 million Series A financing round. The financing will support the continued development of SonoThera's ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.

Get a FREE Sample Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=1593765

"The vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process during the forecast period"

In 2022, vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process in the global viral vector and plasmid DNA manufacturing market. Vector amplification, editing, and expansion are critical steps in viral vector and plasmid DNA manufacturing as they directly impact the quantity, quality, and functionality of the vectors. The pharmaceutical and biopharmaceutical industry is witnessing significant advancements, particularly in the development of novel therapeutics and vaccines. Viral vectors and plasmid DNA are crucial tools for delivering therapeutic genes or vaccine antigens. The demand for vector amplification, editing, and expansion is driven by the need to produce a diverse range of viral vectors and plasmid DNA for various therapeutic and vaccine candidates.

"Europe: The second largest region in the viral vector and plasmid DNA manufacturing market"

Europe accounted for the second-largest market for viral vector and plasmid DNA manufacturing market after North America. The European viral vector and plasmid DNA manufacturing market has witnessed significant growth in recent years, driven by various factors that have propelled its expansion. Europe is at the forefront of developing and adopting emerging technologies in the field of viral vector and plasmid DNA manufacturing market. This includes advancements in viral vector and plasmid DNA manufacturing gtechnologies. The adoption of these innovative technologies accelerates the progress of viral vector and plasmid DNA manufacturing research and expands its applications. Additionally, Europe offers comprehensive training and education programs in viral vector and plasmid DNA manufacturing. Universities, research institutes, and organizations provide funding, and conferences to enhance the knowledge and skills of scientists and researchers. The availability of funding promotes the adoption and utilization of of viral vector and plasmid DNA manufacturing technologies in Europe.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: C-level - 45%, D-level - 30%, and Others - 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

List of Companies Profiled in the Report:
Lonza Group (Switzerland)
Thermo Fisher Scientific Inc. (US)
Merck KGaA (Germany)
Oxford Biomedica (UK)
FUJIFILM Corporation (Japan)
Charles River Laboratories International, Inc. (US)
Danaher Corporation (US)
Genscript Biotech Corporation (US)
SIRION BIOTECH (Germany)
Catalent, Inc (US)
Novartis AG (Switzerland)
Precision Biosciences (US)
Takara Bio Inc. (japan)
Bluebird Bio, Inc. (US)
Sartorius AG (Germany)
VGXI, INC. (US)
Waisman Biomanufacturing (US)
Kaneka Eurogentec S.A. (Belgium)
PlasmidFactory GmbH (Germany)
WuXi AppTec (China)
Atum (US)
Addgene (US)
Cell and Gene Therapy Catapult (US)
Batavia Biosciences B.V. (Netherlands)
Altogen Biosystems (US)

Research Coverage:
This report provides a detailed picture of the viral vector and plasmid DNA manufacturing market. It aims at estimating the size and future growth potential of the market across different segments such as the type, product & service, workflow, application, disease indication, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Avail a 25% Discount on the Direct Purchase of the Global Viral Vector Manufacturing Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=1593765

+ 1 347 333 3771
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.